Chemomab TherapeuticsCMMB
13F holders, Q1 2024 (March 31)14holders
$0.78avg. 13F price*
At the end of Q1 2024, 14 institutions reported holding Chemomab Therapeutics Ltd. (CMMB) in their 13F filings. The largest holders were Orbimed Advisors LLC ($1.7M), Ikarian Capital, LLC ($166K) and Two Sigma Investments, LP ($31K).
- Company
- Chemomab Therapeutics Ltd.
- CUSIP
- 16385C104
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $29K |
| Exits | 5 | $55K |
Ownership 14 holders
| Orbimed Advisors LLC | 0.03% | No change | 2,241,274 | $1.7M |
| Ikarian Capital, LLC | 0.05% | No change | 213,392 | $166K |
| Two Sigma Investments, LP | 0.00% | Reduce -29.0% | 39,994 | $31K |
| Two Sigma Advisers, LP | 0.00% | Add +6.8% | 37,800 | $29K |
| Kestra Private Wealth Services, LLC | 0.00% | No change | 31,241 | $24K |
| Boothbay Fund Management, LLC | 0.00% | No change | 26,529 | $21K |
| Two Sigma Securities, LLC | 0.00% | New | 26,185 | $20K |
| Rhumbline Advisers | 0.00% | No change | 18,627 | $15K |
| Geode Capital Management, LLC | 0.00% | No change | 11,737 | $9K |
| Susquehanna International Group, LLP | 0.00% | New | 11,477 | $9K |
| Morgan Stanley | 0.00% | Reduce -96.1% | 2,797 | $2K |
| Moser Wealth Advisors, LLC | 0.00% | No change | 500 | $390 |
| Qube Research & Technologies Ltd | 0.00% | No change | 44 | $34 |
| JPMorgan Chase & Co. | 0.00% | New | 1 | $1 |
"% of holder's portfolio" is CMMB's weight in each manager's 13F, not the share of Chemomab Therapeutics Ltd. the manager owns.